BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38297200)

  • 1. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of c aspofungin combined with TMP/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia.
    Jin F; Liu XH; Chen WC; Fan ZL; Wang HL
    Int J Infect Dis; 2019 Nov; 88():141-148. PubMed ID: 31442630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
    Tian Q; Si J; Jiang F; Xu R; Wei B; Huang B; Li Q; Jiang Z; Zhao T
    HIV Med; 2021 Apr; 22(4):307-313. PubMed ID: 33277811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
    Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
    Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.
    Qi H; Dong D; Liu N; Xu Y; Qi M; Gu Q
    BMC Infect Dis; 2023 Jun; 23(1):409. PubMed ID: 37328748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
    Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
    BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta-analysis.
    Tritle BJ; Hejazi AA; Timbrook TT
    Transpl Infect Dis; 2021 Dec; 23(6):e13737. PubMed ID: 34553814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.
    Lu YM; Lee YT; Chang HC; Yang HS; Chang CY; Huang CM; Wei J
    Transplant Proc; 2017 Oct; 49(8):1893-1898. PubMed ID: 28923644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VV-ECMO combined with prone position ventilation in the treatment of Pneumocystis jirovecii pneumonia: A case report.
    Jia L; Zhang Z; Bai Y; Du Q
    Medicine (Baltimore); 2022 Jan; 101(1):e28482. PubMed ID: 35029898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
    Dilworth TJ; Ibrahim OM; Mercier RC
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of
    Wu HH; Fang SY; Chen YX; Feng LF
    World J Clin Cases; 2022 Mar; 10(9):2743-2750. PubMed ID: 35434110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
    Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
    Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.
    Liu A; Sun R; Cao G; Liu X; Zhu H; Yang J
    BMC Infect Dis; 2022 Jun; 22(1):546. PubMed ID: 35701759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose trimethoprim-sulfamethoxazole for the treatment of
    Sohani ZN; Butler-Laporte G; Aw A; Belga S; Benedetti A; Carignan A; Cheng MP; Coburn B; Costiniuk CT; Ezer N; Gregson D; Johnson A; Khwaja K; Lawandi A; Leung V; Lother S; MacFadden D; McGuinty M; Parkes L; Qureshi S; Roy V; Rush B; Schwartz I; So M; Somayaji R; Tan D; Trinh E; Lee TC; McDonald EG
    BMJ Open; 2022 Jul; 12(7):e053039. PubMed ID: 35863836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.